Ignite Creation Date:
2024-05-06 @ 8:11 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06289894
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-03-04
First Post:
2024-02-26
Brief Title:
A Study of BRY805 in Participants With Advanced Solid Tumors
Sponsor:
BioRay Pharmaceutical Co Ltd
Organization:
BioRay Pharmaceutical Co Ltd
Study Overview
Official Title:
A Phase I Open-label Single Arm Study to Evaluate the Safety Tolerability and Antitumor Activity of BRY805 in Participants With Advanced Solid Tumors
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase 1 open label multicenter study to evaluate safety tolerance and the maximum tolerance of BRY805 administered intravenously IV once every three weeks in participants with advanced solid tumors so as to confirm the recommended phase 2 dose of BRY805 and obtain the preliminary efficacy information of participants with advanced solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None